Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Ton Langerak; M Ritgen; V Goede; S Robrecht; J Bahlo; K Fischer; M Steurer; M Trneny; SP Mulligan; UJM Mey; K Trunzer; G Fingerle-Rowson; K Humphrey; S Stilgenbauer; S Bottcher; M Bruggemann; M Hallek; M Kneba; Jacques Dongen

doi:10.1182/blood-2018-03-839688

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Ton Langerak, M Ritgen, V Goede, S Robrecht, J Bahlo, K Fischer, M Steurer, M Trneny, SP Mulligan, UJM Mey, K Trunzer, G Fingerle-Rowson, K Humphrey, S Stilgenbauer, S Bottcher, M Bruggemann, M Hallek, M Kneba, Jacques Dongen

Immunology

Research output: Contribution to journal › Article › Academic › peer-review

35 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	494-497
Number of pages	4
Journal	Blood
Volume	133
Issue number	5
DOIs	https://doi.org/10.1182/blood-2018-03-839688
Publication status	Published - 2019

Research programs

EMC MM-02-72-01

Access to Document

10.1182/blood-2018-03-839688

http://hdl.handle.net/1765/115022

Cite this

Langerak, T., Ritgen, M., Goede, V., Robrecht, S., Bahlo, J., Fischer, K., Steurer, M., Trneny, M., Mulligan, SP., Mey, UJM., Trunzer, K., Fingerle-Rowson, G., Humphrey, K., Stilgenbauer, S., Bottcher, S., Bruggemann, M., Hallek, M., Kneba, M., & Dongen, J. (2019). Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood, 133(5), 494-497. https://doi.org/10.1182/blood-2018-03-839688

@article{6c6bc0851f644578bbaac8b5437a24ad,

title = "Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab",

author = "Ton Langerak and M Ritgen and V Goede and S Robrecht and J Bahlo and K Fischer and M Steurer and M Trneny and SP Mulligan and UJM Mey and K Trunzer and G Fingerle-Rowson and K Humphrey and S Stilgenbauer and S Bottcher and M Bruggemann and M Hallek and M Kneba and Jacques Dongen",

year = "2019",

doi = "10.1182/blood-2018-03-839688",

language = "Undefined/Unknown",

volume = "133",

pages = "494--497",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "5",

}

Langerak, T, Ritgen, M, Goede, V, Robrecht, S, Bahlo, J, Fischer, K, Steurer, M, Trneny, M, Mulligan, SP, Mey, UJM, Trunzer, K, Fingerle-Rowson, G, Humphrey, K, Stilgenbauer, S, Bottcher, S, Bruggemann, M, Hallek, M, Kneba, M & Dongen, J 2019, 'Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab', Blood, vol. 133, no. 5, pp. 494-497. https://doi.org/10.1182/blood-2018-03-839688

TY - JOUR

T1 - Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

AU - Langerak, Ton

AU - Ritgen, M

AU - Goede, V

AU - Robrecht, S

AU - Bahlo, J

AU - Fischer, K

AU - Steurer, M

AU - Trneny, M

AU - Mulligan, SP

AU - Mey, UJM

AU - Trunzer, K

AU - Fingerle-Rowson, G

AU - Humphrey, K

AU - Stilgenbauer, S

AU - Bottcher, S

AU - Bruggemann, M

AU - Hallek, M

AU - Kneba, M

AU - Dongen, Jacques

PY - 2019

Y1 - 2019

U2 - 10.1182/blood-2018-03-839688

DO - 10.1182/blood-2018-03-839688

M3 - Article

C2 - 30455380

SN - 0006-4971

VL - 133

SP - 494

EP - 497

JO - Blood

JF - Blood

IS - 5

ER -